0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD19

CD19

CD19 Molecule Information

Name:B-lymphocyte antigen CD19
Target Synonym:CD19?T-cell surface antigen Leu-12?Differentiation antigen CD19?CD19 Molecule?B-Lymphocyte Surface Antigen B4?CD19 Antigen?B-Lymphocyte Antigen CD19?CVID3?B4?Antigens? CD19
Number of Launched Drugs:6
Number of Drugs in Clinical Trials:159
Lastest Research Phase:Approved

CD19 Protein Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
CD9-C5221 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CD19 (20-292) Protein, His Tag
CD9-C5221-structure
CD9-C5221-sds
MBS-K005 Human CD19 protein-coupled magnetic beads
CD9-H82E9 Human Biotinylated Human CD19 (20-291) Protein, His,Avitag™ (SPR verified)
CD9-H82E9-structure
CD9-H82E9-sds
CD9-H82E9-elisa_1
CD9-H82E9-elisa_2
CD9-HP2H3 Human PE-Labeled Human CD19 (20-291) Protein, His Tag
CD9-HP2H3-structure
CD9-H82F7 Human Biotinylated Human CD19 (20-291) Protein, Fc,Avitag™
CD9-H82F7-structure
CD9-H82F7-sds
CD9-H82F7-elisa_1
CD9-H82F7-elisa_2
CD9-H5258 Human Human CD19 (20-291) Protein, Mouse IgG2a Fc Tag
CD9-H5258-structure
CD9-H5258-sds
CD9-H5258-elisa_1
CD9-HF251 Human FITC-Labeled Human CD19 (20-291) Protein, Fc Tag DMF Filed
CD9-HF251-structure
CD9-HF251-sds
CD9-HF2H2 Human FITC-Labeled Human CD19 (20-291) Protein, His Tag DMF Filed
CD9-HF2H2-structure
CD9-HF2H2-sds
CD9-H5251 Human Human CD19 (20-291) Protein, Fc Tag, low endotoxin (Super affinity) DMF Filed
CD9-H5251-structure
CD9-H5251-sds
CD9-H5251-elisa_1
CD9-H5251-elisa_2
CD9-H5250 Human Human CD19 (20-291) Protein, Llama IgG2b Fc Tag, low endotoxin
CD9-H5250-structure
CD9-H5250-sds
CD9-H5250-elisa_1
CD9-H5250-elisa_2
CD9-H52H2 Human Human CD19 (20-291) Protein, His Tag DMF Filed
CD9-H52H2-structure
CD9-H52H2-sds
CD9-H52H2-elisa_1
CD9-H52H2-elisa_2
CD9-C5251 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CD19 (20-292) Protein, Fc Tag
CD9-C5251-structure
CD9-C5251-sds
CD9-H8259 Human Biotinylated Human CD19, Fc Tag, ultra sensitivity (primary amine labeling) DMF Filed
CD9-H8259-structure
CD9-H8259-sds
CD9-H8259-elisa_1
CD9-H5259 Human Human CD19 (20-291) Protein, Fc Tag, low endotoxin
CD9-H5259-structure
CD9-H5259-sds
CD9-H5259-elisa_1
CD9-H5259-elisa_2

CD19 Part of Bioactivity data

CD9-HF251-Cell-based assay
Evaluation of CAR expression

293 cells were transfected with anti-CD19-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human CD19 (20-291), Fc Tag (Cat. No. CD9-HF251, 10 µg/ml) and C. FITC-labeled protein control. A. Non-transfected 293 cells and C. FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-CD19-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human CD19 (20-291), Fc Tag (Cat. No. CD9-HF251) (QC tested).

CD9-H82E9-SPR
Human_FcRn_Heterodimer_Protein_SPR

Biotinylated Human CD19 (20-291), His,Avitag (Cat. No. CD9-H82E9) captured on Biotin CAP - Series S sensor Chip can bind FMC63 MAb (mouse lgG2a) with an affinity constant of 0.255 nM as determined in a SPR assay (Biacore 8K) (QC tested).

CD9-H82F7-SPR
Human_FcRn_Heterodimer_Protein_SPR

Biotinylated Human CD19 (20-291), Fc,Avitag (Cat. No. CD9-H82F7) captured on Biotin CAP - Series S sensor Chip can bind FMC63 MAb (mouse lgG2a) with an affinity constant of 0.177 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

CD19 Customer Reviews

CD19 Molecule Synonym Name

CD19,B4,CVID3,MGC12802

CD19 Molecule Background

B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I  membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.

CD19 References

CD19 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tafasitamab XmAb-5574; MOR-208; XENP-5574; MOR-00208 Approved Xencor MONJUVI United States Lymphoma, Large B-Cell, Diffuse s:27:"Morphosys, Morphosys Us Inc"; 2020-07-31 Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Brexucabtagene autoleucel KTE-X19 Approved Kite Pharma Inc Tecartus United States Lymphoma, Mantle-Cell s:15:"Kite Pharma Inc"; 2020-07-24 Lymphoma, Mantle-Cell Details
Tisagenlecleucel LG-740; CART-19; CTL-019; CART-019 Approved University Of Pennsylvania, Novartis Pharma Ag Kymriah EU Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse s:22:"Novartis Europharm Ltd"; 2017-08-30 Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
Blinatumomab MT-103; AMG-103; MEDI-538; BiTE-MT-103; bscCD19xCD3 Approved Amgen Inc Blincyto Japan Precursor Cell Lymphoblastic Leukemia-Lymphoma s:9:"Amgen Inc"; 2014-12-03 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Axicabtagene ciloleucel KTE-C19; KTE C19 Approved Cabaret Biotech Yescarta EU Lymphoma, Large B-Cell, Diffuse s:17:"Kite Pharma Eu Bv"; 2017-10-18 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Inebilizumab 16C4-aFuc; MEDI-551; MT-0551; VIB-0551 Approved Duke University Uplizna United States Neuromyelitis Optica s:9:"Viela Bio"; 2020-06-11 Lymphoma, B-Cell; Hematologic Neoplasms; Myasthenia Gravis; Rejection of renal transplantation; Immunoglobulin G4-Related Disease; Lymphoma, Large B-Cell, Diffuse; Scleroderma, Systemic; Multiple Sclerosis; Neuromyelitis Optica; Leukemia, Lymphocytic, Chronic, B-Cell Details

CD19 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-human CD19-CD22 T cell therapy Phase 1 Clinical Hrain Biotechnology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
CLIC-1901 (Ottawa Hospital Research Institute) CLIC-1901 Phase 2 Clinical Ottawa Hospital Research Institute Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
UCART-19 S-68587; UCART-19 Phase 1 Clinical Cellectis Leukemia, Lymphoid; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19-STAR-T cell therapy (China Immunotech Co., Ltd.) Phase 1 Clinical Hebei Yanda Hospital, China Immunotech Co Ltd Lymphoma, B-Cell Details
Anti-CD19 CAR-T cell therapy (Bioceltech) Clinical Bioceltech Therapeutics Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19 CAR-T cell therapy (National University of Malaysia) Phase 3 Clinical National University Of Malaysia Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 universal CAR-T cell therapy (Chongqing Xinqiao Hospital) Phase 1 Clinical Chongqing Xinqiao Hospital Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) ICTCAR-014 Phase 2 Clinical Innovative Cellular Therapeutics Co Ltd Lymphoma, Non-Hodgkin Details
4G7SDIE Clinical Synimmune, The University Of Tubingen Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
TI-1007 TI-1007 Phase 2 Clinical Timmune Biotech Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
MC-19PD1 CAR-T cell therapy (Peking University) Phase 1 Clinical Peking University Lymphoma, B-Cell Details
CD19 CARvac T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics Lymphoma, B-Cell; Leukemia, B-Cell Details
Anti-CD19 CAR-T therapy (Wuhan Sian Medical Technology) Phase 2 Clinical Wuhan Sian Medical Technology, Xiangyang Central Hospital, Jingzhou Central Hospital, Wuhan Union Hospital, The First People'S Hospital Of Yuhang District Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR T-cell therapy (Leidos Biomedical Research) Clinical Leidos Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
GNC-038 GNC-038 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) Phase 2 Clinical People'S Liberation Army General Hospital Military Service Leukemia; Lymphoma Details
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell Details
Anti-CD22/CD19 monoclonal antibody-toxin conjugate Phase 1 Clinical Ut Southwestern Medical Center Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
AMG-562 AMG-562 Phase 1 Clinical Amgen Inc Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell Details
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) Phase 1 Clinical Tianjin Mycure Medical Technology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
PCAR-019 (Anke Biotechnology) Phase 1 Clinical Anhui Anke Biotechnology (Group)Co Ltd Lymphoma, Large B-Cell, Diffuse; Leukemia, Prolymphocytic, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 chimeric antigen receptor T cell therapy (Immune cell) Phase 1 Clinical Immune Cell Lymphoma, B-Cell; Leukemia, Lymphoid; Leukemia, B-Cell Details
CD19-CAR-T cell therapy (China Immunotech Co., Ltd.) Phase 1 Clinical China Immunotech Co Ltd, Hebei Yanda Ludaopei Hospital Lymphoma, B-Cell Details
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) Phase 2 Clinical The University Of Texas M.D. Anderson Cancer Center Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) Phase 2 Clinical The First Affiliated Hospital Of Nanchang University Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma Details
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) Phase 1 Clinical Seattle Children'S Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
K193 bispecific antibody K-193 Phase 1 Clinical Beijing Lvzhu Biological Technology Co Ltd Lymphoma, B-Cell Details
CD19 CAR-T cell therapy (Chongqing Precision Biotech) Phase 2 Clinical Chongqing Precision Biotechnology Co Ltd Lymphoma, B-Cell; Leukemia; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
A-319 A-319 Phase 1 Clinical Generon Corp Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
PBCAR-0191 PBCAR-0191 Phase 2 Clinical Baxalta Hematologic Neoplasms; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin Details
Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Fred Hutchinson Cancer Research Center) Phase 1 Clinical Fred Hutchinson Cancer Research Center Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
XYF19 CAR-T cell therapy (Xijing Hospital) Phase 1 Clinical Xijing Hospital Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) Phase 1 Clinical Hrain Biotechnology Leukemia, Lymphoid Details
Anti-CD19 CAR-T cell therapy (iCarTAB BioMed) Phase 1 Clinical Icar Bio, China Leukemia; Lymphoma Details
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) Phase 2 Clinical Southwest Hospital Chongqing Lymphoma, Large B-Cell, Diffuse Details
Anti-CD19 CAR-T cell therapy (Zhongyuan Union Cell & Gene Engineering) Phase 1 Clinical Institute Of Hematology & Blood Diseases Hospital Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
BZ019 BZ-019 Phase 1 Clinical Shanghai Cell Therapy Research Institute Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, Follicular Details
Anti-CD19 CAR T cell therapy (Wuhan Bio-Raid) Phase 2 Clinical Wuhan Bio-Raid Biotechnology Hematologic Diseases; Lymphoma, B-Cell Details
CD19-CAR CD19-CAR Phase 1 Clinical The University Of Texas M.D. Anderson Cancer Center Leukemia; Lymphoma Details
CTA-101 CTA-101 Phase 1 Clinical Nanjing Bioheng Biotech, Xuzhou Medical University (Xzmu), Nanjing Medical University Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
YTB-323 YTB-323 Phase 1 Clinical Novartis Pharma Ag Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
ET-019002 ET-019002 Phase 1 Clinical Eureka Therapeutics Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
1928-zT-2 (Guangzhou Institutes of Biomedicine and Health) Phase 1 Clinical Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR-T cell therapy (Sinobioway) Phase 2 Clinical Sinobioway Biomedicine Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma Details
Obexelimab AMG-729; XmAb-5871 Phase 3 Clinical Xencor Immunoglobulin G4-Related Disease; Arthritis, Rheumatoid; Autoimmune Diseases; Lupus Erythematosus, Systemic Details
aCD19z aCD19z Phase 1 Clinical Christie Hospital Nhs Foundation Trust Lymphoma, Non-Hodgkin Details
Anti-CD19 CAR T-cell therapy (Fujian Medical University) Phase 3 Clinical Fujian Medical University Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR-T cell therapy (Uppsala University) Phase 2 Clinical Uppsala University Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
PTG-01 PTG-01 Phase 1 Clinical Protheragen Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Autologous anti-CD19 chimeric antigen receptor T-cell therapy (Malaghan Institute of Medical Research) WZTL002-1 Phase 1 Clinical The Malaghan Institute Of Medical Research Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin Details
Anti CD19 chimeric antigen receptor T cell therapy (Gracell Biotechnology) Phase 1 Clinical Genxi Biotechnology (Shanghai) Co Ltd Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
MB-CART2019.1 MB-CART2019.1 Phase 2 Clinical Miltenyi Biotec Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
anti-CD19 CAR T-cell (Henan Cancer Hospital) Phase 2 Clinical Shenzhen Prekin Biopharmaceutical Co Ltd, Henan Provincial Cancer Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
TG-1801 NI-1701; TG-1801 Phase 1 Clinical Novimmune Lymphoma, B-Cell Details
GTB-1550 DT-2219; OXS-1550; DT-2219ARL; IND-100780 Phase 2 Clinical University Of Minnesota Leukemia; Lymphoma, B-Cell Details
4-1BBz CD19-Her2tG (Seattle Children's Hospital) Phase 1 Clinical Seattle Children'S Hospital Neoplasms Details
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) Phase 1 Clinical First Affiliated Hospital Of Zhejiang University Lymphoma, Large B-Cell, Diffuse Details
GNR-084 GNR-084 Phase 2 Clinical Generium Pharmaceuticals, Iontas Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
AUTO-1 AUTO1; AUTO-1 Phase 2 Clinical University College London Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 redirected NK cell therapy (National University Health System, Singapore) Phase 1 Clinical National University Health System Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR T-cell therapy (Hebei Senlang Biotechnology) SENL-B19 Phase 2 Clinical Hebei Senlang Biological Technology Co Ltd Leukemia; Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma Details
Anti-CD19 CAR CIK-cell therapy (Formula Pharmaceuticals) CARCIK-CD19; CIK-CAR.CD19 Phase 2 Clinical Fondazione Matilde Tettamanti Menotti De Marchi Onlus Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Coltuximab ravtansine SAR-3419; huB4-DM4 Phase 2 Clinical Immunogen Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin Details
Anti-CD19 CAR-T cell therapy (Bellicum Pharmaceuticals) BPX-401 Phase 2 Clinical Bellicum Pharmaceuticals, Ospedale Pediatrico Bambino Gesu Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma Details
PCAR-119 (PersonGen Biomedicine) PCAR-119 Phase 2 Clinical Leukemia; Lymphoma, Large B-Cell, Diffuse; Leukemia, Prolymphocytic, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 CAR T-cell therapy (Shenzhen Institute for Innovation and Translational Medicine) yinnuokati-19 Phase 2 Clinical Dongguan People'S Hospital, Shenzhen Institute For Innovation & Translational Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) Phase 1 Clinical Zhejiang University Multiple Myeloma Details
GC-007F (Gracell Biotechnology) GC-007F Phase 1 Clinical Genxi Biotechnology (Shanghai) Co Ltd Lymphoma, B-Cell Details
AFM-11 AFM-11 Phase 1 Clinical Affimed Leukemia, B-Cell; Lymphoma, Non-Hodgkin Details
CD19-TriCAR-T/SILK Cell Therapy(Timmune Biotech) Phase 1 Clinical Timmune Biotech Leukemia; Lymphoma, Non-Hodgkin Details
CD19 chimeric antigen receptor T cell therapy (Takara Bio) TBI-1501 Phase 2 Clinical Memorial Sloan Kettering Cancer Center, Takara Bio Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CD19/CD20 Dual-CAR-T cell therapy (HeBei Yanda hospital) Phase 1 Clinical Hebei Yanda Hospital Lymphoma, B-Cell Details
CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) Phase 2 Clinical National Institute Of Allergy And Infectious Diseases, University Of Pittsburgh Immunologic Deficiency Syndromes Details
HuCART19 Phase 2 Clinical National Cancer Institute, Kite Pharma Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) Phase 1 Clinical The Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics Multiple Myeloma; Lymphoma Details
pCAR-19B Phase 1 Clinical Chongqing Precision Biotechnology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
PBLTT52CAR19 Phase 1 Clinical Great Ormond Street Hospital For Children Nhs Foundation Trust Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics Lymphoma, B-Cell; Leukemia; Leukemia, B-Cell Details
CTL-119 CTL-119 Phase 2 Clinical University Of Pennsylvania, Novartis Pharma Ag Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
IM19CAR-T Phase 2 Clinical Beijing Yimiao Medical Technology Co Ltd Leukemia; Hematologic Neoplasms; Lymphoma, Non-Hodgkin Details
Humanized CD19 CAR-T cell therapy (Yake) YK-C19 Phase 1 Clinical Yake Biotechnology Lymphoma, B-Cell; Leukemia, Lymphoid Details
Murine CD19 CAR-T cell therapy (Yake) Phase 1 Clinical Yake Biotechnology Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Anti-CD19 chimeric antigen receptor T cell therapy (Wuhan Sian Medical Technology) Phase 1 Clinical Wuhan Sian Medical Technology Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Virus-specific-CD19.CAR Phase 1 Clinical Baylor College Of Medicine Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
H-31970-SAGAN H-31970-SAGAN Phase 1 Clinical Baylor College Of Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Allogeneic EBV-specific anti-CD19 CAR-T cell therapy (Memorial Sloan-Kettering Cancer Center) Phase 1 Clinical Memorial Sloan Kettering Cancer Center Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) Phase 1 Clinical Fujian Medical University Lymphoma, Large B-Cell, Diffuse Details
Anti-CD19 CAR T-cell therapy (Sheba Medical Center) Phase 3 Clinical Chaim Sheba Medical Center At Tel Hashomer Leukemia, Myeloid, Acute Details
Anti-CD19 CAR T-cell therapy (University College London) 4G7-CARD Phase 1 Clinical University College London Lymphoma Details
Anti-CD19 CAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) 4SCAR-19 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell Details
ET190L1-ARTEMIS T cells (Eureka Therapeutics) ET190; ET-190; ET190L1; ET190L1-ARTEMI Phase 1 Clinical Eureka Therapeutics Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
AUTO-3 AUTO-3 Phase 2 Clinical University College London Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
TAK-007 TAK-007 Phase 2 Clinical University Of Texas M. D. Anderson Cancer Center Lymphoma, B-Cell Details
RO-7227166 RO-7227166 Phase 1 Clinical F. Hoffmann-La Roche Ltd Lymphoma, Non-Hodgkin Details
CD19-targeting humanized selective CAR-T cell therapy (Xuanwu Hospital, Beijing) Phase 2 Clinical Xuanwu Hospital Of Capital Medical University Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Leukemia; Lymphoma, B-Cell Details
Duvortuxizumab MGD-011; JNJ-64052781 Phase 1 Clinical Macrogenics Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 CAR T cell therapy (Shanghai GeneChem) Phase 2 Clinical Shanghai Genechem Co Ltd Lupus Erythematosus, Systemic; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) Phase 1 Clinical City Of Hope National Medical Center Lymphoma, Non-Hodgkin Details
CART-19 cells (Henan Hualong Biotechnology) Phase 2 Clinical Henan Hualong Biotechnology Leukemia, Lymphoid Details
Anti-CD19 CAR T-cell therapy (Shanghai Children's Medical Center) Phase 2 Clinical Shanghai Children'S Medical Center, Miltenyi Biotec Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 CAR-T cell therapy (Juno Therapeutics) Phase 1 Clinical Juno Therapeutics Hematologic Neoplasms Details
Anti-CD19 CAR T-cell therapy (Southwest Hospital Chongqing) Phase 2 Clinical Southwest Hospital Chongqing Lymphoma, Large B-Cell, Diffuse Details
Anti CD19 chimeric antigen receptor T cell therapy (Beijing Boren Hospital) Phase 2 Clinical Beijing Boren Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR-T cell therapy (Japan Tissue Engineering) Phase 1 Clinical Nagoya University, Shinshu University Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19 CAR-T cell therapy (The First Affiliated Hospital of Soochow University) Phase 2 Clinical Suzhou University Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells TAK-940 Phase 1 Clinical Takeda Neoplasms Details
CD19 UCAR-T cell therapy (Shanghai Longyao Biotechnology) Phase 1 Clinical Shanghai Longyao Biotechnology Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR-T cell therapy (Shanghai Bioray Laboratory) Phase 2 Clinical Shanghai Bioray Laboratory Inc Leukemia Details
Anti-CD19 CAR T-cell therapy (Nanjing CART Medical Technology) Clinical Nanjing Cart Medical Technology Neoplasms Details
CAR-CD19 T cell therapy Phase 2 Clinical Carsgen Biomedicine (Shanghai) Co Ltd Lymphoma, Non-Hodgkin Details
CD19.CAR-VST CD19.CAR-VST Phase 1 Clinical Baylor College Of Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) Phase 1 Clinical Uclas Jonsson Comprehensive Cancer Center Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19-CAR T cell therapy (Kecellitics Biotech) Phase 1 Clinical Kecellitics Biotech Company Ltd Leukemia; Lymphoma Details
Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology) Clinical Hebei Senlang Biological Technology Co Ltd Leukemia Details
Senl-1904A Senl-1904A; Senl_1904A Phase 1 Clinical Hebei Senlang Biological Technology Co Ltd Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
TAC01-CD19 TAC01-CD19 Phase 2 Clinical Triumvira Immunologics Lymphoma, B-Cell Details
Anti-CD19 CAR T-cell therapy (Nanjing Medical University) XLCART-001 Phase 2 Clinical Nanjing Medical University Lymphoma, B-Cell Details
ICT19G1 ICT-19G1 Phase 1 Clinical Innovative Cellular Therapeutics Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) Phase 1 Clinical Stanford University Lymphoma, B-Cell Details
CD19 CAR-T cell (Pregene) Phase 2 Clinical Shenzhen Prekin Biopharmaceutical Co Ltd Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) Phase 1 Clinical The First Affiliated Hospital Of Nanchang University Multiple Myeloma Details
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) Phase 1 Clinical Henan Provincial Cancer Hospital Lymphoma, B-Cell Details
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) Phase 2 Clinical The Medical College Of Wisconsin Nonprofit Neoplasms Details
CLBR-001/SWI-019 CLBR-001/SWI-019 Phase 1 Clinical California Institute For Biomedical Research, Abbvie Inc Lymphoma, B-Cell Details
GC-012F GC-012F Phase 1 Clinical Genxi Biotechnology (Shanghai) Co Ltd Multiple Myeloma Details
CAR-T 19 cell therapy (University of Pennsylvania) Phase 2 Clinical University Of Pennsylvania Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
CD19.CAR T Cells (University Hospital Heidelberg) Phase 2 Clinical University Of Heidelberg Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
U-CART (Shanghai Bioray Laboratory Inc) Phase 2 Clinical Shanghai Bioray Laboratory Inc Hematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR-T cell therapy (Pinze Lifetechnologies) PZ-01 Clinical Pinze Lifetechnology Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy GC-197 Phase 2 Clinical Genxi Biotechnology (Shanghai) Co Ltd Lymphoma, B-Cell; Leukemia, B-Cell Details
iPD1 CD19 eCAR-T therapy (Marino Biotechnology) Phase 1 Clinical Beijing Mali Biotechnology Co Ltd, Chengdu Yinhe Biomedicine Co Ltd Lymphoma, B-Cell Details
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) Phase 1 Clinical Shanghai Jiaotong University Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (University of Alberta) Phase 2 Clinical University Of Alberta Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Anti-CD19 CAR-T Cells (Yan'an Affiliated Hospital of Kunming Medical University) Phase 1 Clinical Kunming Medical University Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19-CART Phase 2 Clinical Hrain Biotechnology Co Ltd Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics) Phase 2 Clinical Innovative Cellular Therapeutics Co Ltd, Kunming Medical University, Zhejiang University Leukemia; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin Details
Anti-CD19/CD22 chimeric antigen receptor T cell therapy (Nanjing Legend Biotech) LCAR-L10D Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd, Second Affiliated Hospital Xi'An Jiaotong University Lymphoma, Large B-Cell, Diffuse Details
CD19-CART (IL-6 secretion knockdown, Unicar-Therapy Bio-medicine Technology) Phase 1 Clinical Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR T-cell therapy (Hrain Biotechnology) Phase 2 Clinical Shanghai Zhongshan Hospital, Hrain Biotechnology Candidiasis, Vulvovaginal; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CTA-30X CTA-30X; CTA30X Details
Anti-CD19 CAR-T cell therapy (Juventas) CNCT19; CNCT-19; HY001 Phase 2 Clinical Heyuan Biotechnology (Tianjin) Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
GC007g GC-007G Phase 1 Clinical Genxi Biotechnology (Shanghai) Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell Details
CC-97540 CC-97540 Phase 1 Clinical Juno Therapeutics Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
CD19/CD20 CAR-T Cell Therapy (PersonGen) Details
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) Phase 1 Clinical China Immunotech Co Ltd Lymphoma, Non-Hodgkin Details
JCAR-014 JCAR-014 Phase 2 Clinical Fred Hutchinson Cancer Research Center, Juno Therapeutics, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) Phase 1 Clinical Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 CAR T-cell therapy (Dana-Farber Cancer Institute/Memorial Sloan-Kettering Cancer Center/Boston Children's Hospital) Phase 2 Clinical Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Boston Children'S Hospital Leukemia Details
3rd-gen-CD19-CAR 3rd-gen-CD19-CAR Phase 2 Clinical Bluebird Bio Lymphoma, B-Cell; Leukemia, B-Cell Details
JCAR-015 JCAR-15; JCAR-015; 19-28z-T-Cells; 19-28z+ T cells; 19-28z CAR T cells Phase 2 Clinical Seattle Children'S Research Institute, Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Research Center, Juno Therapeutics Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) Phase 2 Clinical Shenzhen University General Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) Phase 2 Clinical Shenzhen University General Hospital Lymphoma, B-Cell Details
BinD-19 (Shenzhen BinDeBio) BinD-19 Phase 2 Clinical Shenzhen Bindebio Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
ALLO-501 ALLO-501 Phase 1 Clinical Cellectis Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
TC-110 TC-110 Phase 2 Clinical Tcr2 Therapeutics Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CD19 CAR-T (HuaDao CAR-Tcell) Phase 1 Clinical Huadao (Shanghai) Biopharma Co Ltd Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details

This web search service is supported by Google Inc.

totop